Beta-blockers (All routes except ocular) (versus unexposed) updated on 12-17-2024

Genital anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17127
R71757
Delteil - Beta-blockers, 2024 Genital system malformations 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Indications Antihypertensive: Only chronic indication (hypertension or cardiac) 1.28 [0.41;3.98] C 3/974   400/165,775 403 974
ref
S13935
R54559
Vasilakis-Scaramozza - Beta-blockers, 2013 Genital anomalies 1st trimester retrospective cohort unexposed (general population or NOS) Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified 2.80 [0.70;11.90] 3/215   4/682 7 215
ref
Total 2 studies 1.74 [0.72;4.22] 410 1,189
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Delteil - Beta-blockers, 2024Delteil - Beta-blockers, 2024 1.28[0.41; 3.98]40397461%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Vasilakis-Scaramozza - Beta-blockers, 2013Vasilakis-Scaramozza - Beta-blockers, 2013 2.80[0.70; 11.90]721539%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.74[0.72; 4.22]4101,1890.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.74[0.72; 4.22]4101,1890%NADelteil - Beta-blockers, 2024 Vasilakis-Scaramozza - Beta-blockers, 2013 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.74[0.72; 4.22]4101,1890%NADelteil - Beta-blockers, 2024 Vasilakis-Scaramozza - Beta-blockers, 2013 2 Tags Adjustment   - No  - No 1.28[0.41; 3.98]403974 -NADelteil - Beta-blockers, 2024 1   - Yes  - Yes 2.80[0.68; 11.54]7215 -NAVasilakis-Scaramozza - Beta-blockers, 2013 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 2.80[0.68; 11.54]7215 -NAVasilakis-Scaramozza - Beta-blockers, 2013 1   - Only chronic indication (hypertensi ...  - Only chronic indication (hypertension or cardiac) 1.28[0.41; 3.98]403974 -NADelteil - Beta-blockers, 2024 1 All studiesAll studies 1.74[0.72; 4.22]4101,1890%NADelteil - Beta-blockers, 2024 Vasilakis-Scaramozza - Beta-blockers, 2013 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.74[0.72; 4.22]4101,1890%NADelteil - Beta-blockers, 2024 Vasilakis-Scaramozza - Beta-blockers, 2013 20.510.01.0